Merger Announcement: Vertex to Acquire Crinetics at $85 a Share

Key takeaways

• Vertex Pharmaceuticals filed its merger announcement on Form 8-K on July 7, 2026, disclosing an agreement signed July 6 to acquire Crinetics Pharmaceuticals for $85.00 per share in cash.
• The deal was structured as a one-step merger requiring a Crinetics stockholder vote, not a tender offer.
• Crinetics agreed to a termination fee of $350,474,425 in specified circumstances.
• The merger closed on September 1, 2026, with aggregate consideration of about $10.0 billion funded with cash and term loan borrowings.
• Crinetics stock was suspended from trading on the Nasdaq Global Select Market before the open on the closing date.

The merger announcement

Vertex’s 8-K described a standard structure: Clark Merger Sub, Inc., a Vertex subsidiary, merges into Crinetics, which survives as a wholly owned subsidiary of Vertex. Each Crinetics share converts into the right to receive $85.00 in cash. The filing did not mention contingent value rights, so the price was all upfront cash.

Term	Detail
Agreement date	July 6, 2026
Price per share	$85.00 cash
Structure	One-step merger with stockholder vote
Target termination fee	$350,474,425
Expected closing (at signing)	Third quarter 2026
Actual closing	September 1, 2026
Aggregate consideration	About $10.0 billion

Conditions and protections

Closing required approval by a majority of Crinetics’ outstanding shares, clearance under the Hart-Scott-Rodino Act and certain foreign regulatory approvals, no legal restraints, accurate representations and warranties, and no material adverse effect. Financing was expressly not a condition.

The termination fee was payable by Crinetics in situations such as accepting a superior proposal, a change in its board’s recommendation, or entering into a competing transaction within 12 months after termination. The fee is about 3.5% of the roughly $10.0 billion aggregate consideration reported at closing, by our calculation, in line with typical public company deal protections.

From signing to closing in under two months

The speed of the transaction stands out. Vertex signed on July 6 and closed on September 1, a span of eight weeks that included a stockholder vote and antitrust review. That aligns with the third-quarter closing target in the original 8-K.

According to Crinetics’ closing 8-K, the roughly $10.0 billion in consideration was funded with a combination of cash on hand and borrowings under Vertex’s term loan credit agreement. Crinetics asked Nasdaq to suspend trading before the market opened on September 1 and to file a Form 25 to remove the stock from listing and registration.

A choice of structure

Vertex chose a one-step merger with a stockholder vote rather than a tender offer, which is often faster for cash deals. Even so, the companies closed in about eight weeks. A one-step merger requires a proxy statement and a meeting, but it avoids the minimum-tender condition of an exchange offer. The fast close suggests the regulatory reviews did not raise significant issues.

Why it matters

At about $10.0 billion, the deal reflects a pattern of established drugmakers buying mid-stage and late-stage companies to add revenue sources. For Vertex, the use of term loan borrowings alongside cash shows a willingness to add leverage for a strategic deal. For the biotech sector, a clean, fast close at a fixed cash price signals that large pharmaceutical buyers can still move quickly when antitrust overlap is limited.

What to watch

With the deal closed, attention shifts to Vertex: how it integrates Crinetics’ programs, how quickly it repays the term loan borrowings, and whether it pursues further deal announcements. Vertex’s subsequent quarterly filings will show the accounting for the acquisition and any related charges.